Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Pacira Pharmaceuticals (PCRX) is now available.
Gary Pace announced his plan to retire from the Board of Directors of Pacira BioSciences, Inc., effective June 30, 2024, with no disagreements cited. He will enter into a consulting agreement amendment for a year starting July 1, 2024. Additionally, the 2024 Annual Meeting saw the election of four directors, the ratification of KPMG LLP as the independent auditor, and approval of executive compensation, with a majority of stockholders voting in favor of these proposals.
For an in-depth examination of PCRX stock, go to TipRanks’ Stock Analysis page.